EMA Finalizes AI In Medicines Paper After Reviewing 1,342 Comments
Executive Summary
Many of the comments were very helpful in improving the document in relation to both form and content, the European Medicines Agency said of its newly published reflection paper on the use of artificial intelligence during the drug development, marketing authorization and post-authorization phases.